Veterinarian CFO services: what your clinic is worth to a consolidator — and to you

The consolidator call will come — be ready before it does

Corporate groups have been buying Canadian veterinary practices for years, and owners of profitable clinics should expect the approach rather than be flattered by it. The mistake is engaging unprepared: signing a letter of intent with an exclusivity clause before your own normalized numbers exist means negotiating inside the buyer's model. Our ongoing CFO cadence — monthly accrual statements, provider-level production, consumables tracked as real cost of goods — exists so that when the call comes, you already know what the clinic earns and what a fair offer looks like. It also means fee schedules, drug-cost pass-through, and staffing ratios have been managed all along — buyers pay for trajectory as well as level. Fixed fees, quoted after a discovery call.

Reading the offer: the multiple is the beginning, not the price

A consolidator offer is a machine with several moving parts, and each one can quietly move value away from you. What we pin down line by line:

We model the net outcome under scenarios — earn-out fully paid, partially paid, missed — because the honest value of an offer is its downside case, not its brochure case.

What clean books add to the price

Every dollar of EBITDA you can prove gets multiplied; every dollar the buyer's diligence team doubts gets discounted or re-traded after the LOI, when exclusivity has stripped your leverage. Clean means accrual statements, consumables inventory actually counted so drug and supply costs are real, personal expenses identified as documented add-backs rather than surprises, and production reported by provider. Two years of that record before going to market is the cheapest price increase available. If the books are not there yet, our bookkeeping team rebuilds them first, and our tax team plans the sale structure — a qualifying share sale can shelter up to $1.25 million per shareholder under the lifetime capital gains exemption, which is reason enough to plan the corporate side early.

Staff-shortage economics if you keep it

The alternative to selling is running a clinic in a market where veterinarians are scarce — which means associate compensation is set by the market, not by you, and the controllable lever is how much production each DVM-hour supports. That is a technician-leverage problem: RVTs working to full scope, appointment lengths matched to visit types, and fee discipline that keeps pace with drug and supply inflation instead of absorbing it. We track production per DVM-hour and per exam-room alongside staff cost ratios, because a clinic that solves its leverage problem becomes more valuable on both paths — better income if you keep it, better EBITDA if you sell it. Retention belongs in the model too: the all-in cost of replacing an associate — recruiting, incentives, months of reduced production while the appointment book rebuilds — usually dwarfs the raise that would have kept them, and the numbers should make that visible before the resignation letter does.

When the buyer is American

Many consolidators operating in Canada are US-owned, which adds a layer most offer letters skip: earn-outs or parent equity may be paid from a US entity, equity rolls can leave you holding US securities with their own filing and estate consequences, and the tax character of each payment stream deserves attention before signatures, not after. Our cross-border guide for veterinarians covers the terrain. None of this is a reason to avoid US buyers — they often pay the strongest prices — it is a reason to price the whole package rather than the headline. The broader rule: assemble your advisory team before the LOI, because exclusivity clauses make everything after it a negotiation you attend without alternatives.